Skip to main content
All lobbying filings

FRONTLINE GOVERNMENT RELATIONS

Lobbying for EMPOWER PHARMACY · Compounding pharmacy

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
Texas

Official filing document

 Government bodies contacted 3
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 2
Health Issues

Advocated for clarity and fairness in the regulation of pharmaceutical compounding by the Food and Drug Administration (FDA), including issues related to compliance with Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Manufacturing

Advocated for regulatory clarity and proportional enforcement in the oversight of outsourcing facility manufacturing under Section 503B of the Federal Food, Drug, and Cosmetic Act.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem